Cerevance

Private

Boston, MassachusettsHealthcare & Life Scienceshttps://www.cerevance.com

Last Round

Series C

May 12, 2026

Total Funding Raised

$209.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cerevance is a biotechnology company focused on developing innovative therapeutics to create new treatments for central nervous system diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

CNS therapeuticsdrug discovery platformNETSseqclinical-stage pharmahuman brain tissueneurodegenerative diseasetarget identificationParkinson's diseasepharma partnershipstranscriptomicsAlzheimer's diseaseAI drug discoverybiotechdrug discovery enginecomputational drug discoverydrug licensingneuroinflammationALSsingle-nucleus sequencing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cerevance Comps

Public and private peers based on sector, stage, and business model.

Cerevance comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cerevance Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series C	May 12, 2026
Series B Extension	Apr 25, 2024
Series B Extension	Feb 13, 2023
Series B Extension	Jul 21, 2020
Series B	Apr 14, 2020
VC Round	Feb 21, 2018

View all Funding Rounds

Key People

Founding team and executive leadership

Craig Thompson

Chief Executive Officer

Executive Team

Cerevance Investors

Notable investors and investment history

Cerevance investors
Investor	Rounds
Agent Capital	Series B Extension
Dolby Family Ventures	Series B Extension
SV Health Investors	Series C, Series A, Series B, Series B Extension, VC Round
GV	Series C, Series B Extension, Series B
Lightstone Ventures	Series C, Series B Extension, Series B, Series A
Bioluminescence Ventures	Series B Extension
Bellco Capital	Series B Extension

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 12, 2026
$20M round with participation from GV and UPMC Enterprises.
Apr 18, 2026
Presenting at the American Academy of Neurology 2026 Annual Meeting.

View all signals

Cerevance Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Cerevance Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cerevance's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts

Employee Range35

Year Founded2015

Last FundingMay 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.